Opinion|Videos|August 6, 2024
Key Updates Needed in Chronic Spontaneous Urticaria Guidelines
A panel of experts discuss the key updates needed in CSU guidelines, as they have not been updated since 2014.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- The chronic spontaneous urticaria guidelines have not been updated since 2014. What key updates are needed in the newest version of the guidelines?
Advertisement
Related to this article
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
Multi-Hit TP53 Linked to Shorter Survival in Chronic-Phase MPN Cohorts
4
Navigating GLP-1 Access & Prior Authorizations: Amanda Velazquez, MD
5